R&D channel feed – Endpoints News

R&D channel feed

Sage shares get a bump from a snapshot of new PhII depression data

9 years ago

Zosano shares soar as its pivotal migraine drug patch study comes through

9 years ago

Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger

9 years ago

Intercept ‘lowers the bar’ on its pivotal PhIII OCA study for NASH

9 years ago

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

9 years ago

Daiichi Sankyo shutters another R&D center in an ongoing global overhaul

9 years ago

Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal

9 years ago

Playing catch-up, Regeneron and Sanofi push ahead on pivotal PD-1 cancer studies

9 years ago

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

9 years ago

Bayer, J&J wrap positive PhIII cardio study for Xarelto early, looking to beef up its market

9 years ago

Lundbeck reads last rites on another failed PhIII Alzheimer’s program

9 years ago

Cellectis preps for groundbreaking US trials for an off-the-shelf CAR-T therapy

9 years ago

Bristol-Myers partner Innate concedes a PhII flop for I/O drug lirilumab in fighting AML

9 years ago

After promising Trump new US jobs, Eli Lilly sets out to chop 200 R&D staffers

9 years ago

Amgen scores positive PhIII cardio outcomes for its PCSK9 franchise drug Repatha

9 years ago

Aviragen shares plunge as RSV antiviral flunks a small PhIIa study

9 years ago

Struggling Ophthotech organizes a global hunt for some new opthalmology deals

9 years ago

Catabasis shares are shredded after lead drug flops in PhII Duchenne MD study

9 years ago

Eli Lilly shutters the last PhIII sola study, certain of failure

9 years ago

Tenax endures (another) clinical catastrophe as its PhIII flops, shares blitzed

9 years ago

After a PhII catastrophe wiped out a billion dollars in market cap, Seres is looking for a do-over

9 years ago

Microcap biotech Ocera craters on a PhIIb failure for hepatic encephalopathy

9 years ago

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

9 years ago

Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford

9 years ago

First page Previous page 305 306 307308309 310 311 Next page Last page